JMP Securities analyst Jason Butler reiterated a Buy rating on Syros Pharmaceuticals (SYRS – Research Report) today and set a price target of $16.00. The company’s shares closed today at $3.50.Butler covers the Healthcare … We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Business Of Sports If the only thing you know about sports is who wins and who loses, you are missing the highest stakes action of all. The business owners that power this multibillion dollar industry are changing, and a new era of the business of sports is underway.
Latest SYRS News From Around the Web
Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. These returns cover a period from January 1, 1988 through March 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.
As for revenue growth, note that SYRS’s revenue has grown -36.65% over the past 12 months; that beats the revenue growth of merely 5.94% of US companies in our set. Syros Pharmaceuticals’ stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A.
Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. High-growth stocks tend to represent the technology, healthcare, and communications sectors.
Top 5 4th Quarter Trades of ADAGE CAPITAL PARTNERS GP, L.L.C.
The largest positive contribution comes from its “Physical diseases” impact, which is driven by its “Clinical research services for physical health” product.
It’s calculated by dividing the current share price by the earnings per share . It can also be calculated by dividing the company’s Market Cap by the Net Profit. In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on Syros Pharmaceuticals (SYRS – Research Report), with a price target of $60.00. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The consensus among Wall Street equities research analysts is that investors should “buy” SYRS shares. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.
What is Syros Pharmaceuticals Inc’s stock style?
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services.
7 cheap stocks under 7 with massive upside, Inc. saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further… Syros Pharmaceuticals, Inc. delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the… The technique has proven to be very useful for finding positive surprises. Maintaining independence and editorial freedom is essential to our mission of empowering investor success.
According to 5 analysts, the average rating for SYRS stock is “Strong Buy.” The 12-month stock price forecast is $32.8, which is an increase of 947.92% from the latest price. Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals said in a filing Monday that it expects its initial public offering of stock to price between $14 and $16 a share. The biopharmaceutical company, which has developed a gene-control platform, said it … Syros Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 .
We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS) and COMPASS Pathways (CMPS)
This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies. According to analysts’ consensus price target of $32.80, Syros Pharmaceuticals has a forecasted upside of 941.3% from its current price of $3.15. SYRS’s stock price has decreased by -66.02% in the past year and price targets may not have had time to catch up. Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients…
Real-time analyst ratings, insider transactions, earnings data, and more. 3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company’s employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Syros Pharmaceuticals shares reverse split before market open on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022.
Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of Syros Pharmaceuticals is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Syros Pharmaceuticals has a short interest ratio (“days to cover”) of 5.5. Syros Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment.
Syros Pharmaceuticals expects IPO price of between $14 and $16 a share
Insiders that own company stock include Eric R Olson, Eric R Olson, Mark J Alles, Richard A Young, Srinivas Akkaraju and Timothy Tyson. Sign Up NowGet this delivered to your inbox, and more info about our products and services. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Provides a general description of the business conducted by this company. Barchart is committed to ensuring digital accessibility for individuals with disabilities. We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and accommodation requests. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank.
Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Syros Pharmaceuticals (SYRS – Research Report) today and set a price target of $60.00. The 5 analysts with a stock price forecast for SYRS stock have an average 12-month price target of $32.8, which predicts an increase of 947.92%. On average, analysts rate SYRS stock stock as a strong buy. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades.
- You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.
- The business owners that power this multibillion dollar industry are changing, and a new era of the business of sports is underway.
- This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.
- Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
- Zacks Ranks stocks can, and often do, change throughout the month.
Syros Pharmaceuticals Inc. 50-day moving average is $3.14. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CompareSYRS’s historical performanceagainst its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
Syros Pharmaceuticals, Inc. has been upgraded to a Zacks Rank #2 , reflecting growing optimism about the company’s earnings prospects. The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.SYRS has a Quality Grade of C, ranking ahead of 31.76% of graded US stocks.